Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021
Marker Therapeutics, Inc. (Nasdaq:MRKR) will host a conference call and webcast on May 12, 2021, at 5:00 p.m. ET to discuss its first quarter 2021 financial results and provide a corporate update. Participants can join via the company's website or by calling 877-407-8913 (domestic) or 201-689-8201 (international). After the event, the archived webcast will be available for replay. Marker Therapeutics specializes in developing T cell-based immunotherapies for hematological malignancies and solid tumors, claiming advantages over current engineered therapies.
- Upcoming conference call on May 12, 2021, for financial results review
- Focus on next-generation T cell-based immunotherapies with potential manufacturing advantages
- None.
HOUSTON, April 29, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Wednesday, May 12, 2021 at 5:00 p.m. Eastern Time to review its first quarter 2021 financial and operating results and provide a corporate update.
The webcast will be accessible in the Investors section of the Company's website at markertherapeutics.com. Individuals can participate in the conference call by dialing 877-407-8913 (domestic) or 201-689-8201 (international) and referring to the "Marker Therapeutics First Quarter 2021 Earnings Call."
The archived webcast will be available for replay on the Marker website following the event.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.
View original content to download multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-host-first-quarter-2021-operating-and-financial-results-conference-call-and-webcast-on-wednesday-may-12-2021-301280664.html
SOURCE Marker Therapeutics, Inc.
FAQ
When will Marker Therapeutics hold its Q1 2021 earnings call?
How can I access the Marker Therapeutics earnings call?
What type of therapies does Marker Therapeutics focus on?
Will there be a replay of the Marker Therapeutics earnings call?
